On May 14, 2024 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported the online publication of three abstracts submitted to the European Hematology Association (EHA) (Free EHA Whitepaper) Congress, to be held June 13-16, 2024 (Press release, Autolus, MAY 14, 2024, View Source [SID1234643262]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral presentation:
Title: obecabtagene autoleucel in adult relapsed/refractory B Cell acute lymphoblastic leukemia: Survival and potential impact of CAR-T cell persistence and stem cell transplantation in the FELIX study
Session Title: s419 Acute lymphoblastic leukemia – Clinical 1: Immunotherapy: antibodies and CAR-T cells
Session date and time: Friday, June 14 from 14:45 – 16:00 CEST
Session room: N104
Final Abstract Code: S114
Presenting Author: Dr. Claire Roddie
Poster presentations:
Title: obecabtagene autoleucel (obe-cel, AUTO1) for relapsed/refractory adult B-Cell acute lymphoblastic leukemia (R/R B-ALL): The impact of inotuzumab-containing bridging therapy on treatment outcomes
Session Title: Poster session
Session date and time: Friday, June 14 from 18:00 – 19:00 CEST
Final Abstract Code: P418
Presenting Author: Dr. Jae H. Park
Title: Droplet digital PCR and flow cytometry sensitivity for measuring CAR-T cell kinetics in adult patients with relapsed/refractory B Cell acute lymphoblastic leukemia treated with obecabtagene autoleucel
Session Title: Poster session
Session date and time: Friday, June 14 from 18:00 – 19:00 CEST
Final Abstract Code: P1469
Presenting Author: Dr. Claire Roddie